Table 1.
Demographic, clinical and laboratory characteristics of patients in each outcome group
| Anti-CCP negative RA (n=53) | Anti-CCP positive RA (n=48) | Persistent non-RA (n=66) | Resolving arthritis (n=96) | p Value | |
|---|---|---|---|---|---|
| Female, n (%) | 27 (50.9) | 31 (64.6) | 37 (56.1) | 46 (47.9) | 0.274 |
| Age (years) | 55.6±15.7 | 55.5±14.4 | 52.1±18.9 | 45.9±16.8 | <0.0001 |
| Symptom duration (days) | 52.4±21.4 | 55.3±21.7 | 56.4±21.5 | 45.3±20.8 | 0.005 |
| CRP (mg/dL) | 10 (0–39) | 17.5 (6–43.8) | 20.5 (7.5–35.3) | 7 (0–17) | <0.0001 |
| ESR (mm/hour) | 18 (11.5–44.5) | 27.5 (18.3–51.3) | 21.5 (7.8–45.8) | 12.5 (5–27) | <0.0001 |
| DAS28 (CRP) | 4.4±1.4 | 4.4±1.4 | 3.6±1.2 | 2.8±1.3 | <0.0001 |
| DAS28 (ESR) | 4.6±1.5 | 4.7±1.6 | 3.6±1.8 | 2.9±1.5 | <0.001 |
| Smoking, n (%) | 0.07 | ||||
| Ever smoker | 28/49 (57.1) | 27/47 (57.4) | 26/64 (40.6) | 35/89 (39.3) | |
| Never-smoker | 21/49 (42.9) | 20/47 (42.6) | 38/64 (59.4) | 54/89 (60.7) | |
| Anti-CCP positive, n (%) | 0 (0) | 48 (100) | 1 (1.5) | 1 (1.0) | <0.0001 |
| RF IgG positive, n (%) | 9 (17) | 44 (91.7) | 5 (7.6) | 10 (10.4) | <0.0001 |
| RF IgA positive, n (%) | 7 (13.2) | 26 (54.2) | 5 (7.6) | 10 (10.4) | <0.0001 |
| Anti-cTNC5 positive, n (%) | 2 (3.8) | 39 (81.3) | 4 (6.1) | 3 (3.1) | <0.0001 |
| Anti-rTNC5 positive, n (%) | 1 (1.9) | 1 (2.1) | 3 (4.5) | 1 (1.0) | 0.527 |
Data are shown as number (percentage), mean±SD, or median (IQR) as appropriate. Comparisons have been performed with χ2, analysis of variance (ANOVA) and Kruskal-Wallis tests for categorical, parametric continuous and non-parametric continuous data, respectively.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; cTNC, citrullinated tenascin-C; DAS, disease activity score; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor.